Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HMGB1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HMGB1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HMGB1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HMGB1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HMGB1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HMGB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HMGB1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HMGB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HMGB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/HMGB1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HMGB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HMGB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0070302 | Colorectum | AD | regulation of stress-activated protein kinase signaling cascade | 58/3918 | 195/18723 | 2.21e-03 | 1.74e-02 | 58 |
GO:0032069 | Colorectum | AD | regulation of nuclease activity | 11/3918 | 22/18723 | 2.32e-03 | 1.80e-02 | 11 |
GO:0032872 | Colorectum | AD | regulation of stress-activated MAPK cascade | 57/3918 | 192/18723 | 2.51e-03 | 1.92e-02 | 57 |
GO:0043542 | Colorectum | AD | endothelial cell migration | 78/3918 | 279/18723 | 2.97e-03 | 2.22e-02 | 78 |
GO:1903706 | Colorectum | AD | regulation of hemopoiesis | 99/3918 | 367/18723 | 3.08e-03 | 2.28e-02 | 99 |
GO:0045637 | Colorectum | AD | regulation of myeloid cell differentiation | 61/3918 | 210/18723 | 3.17e-03 | 2.35e-02 | 61 |
GO:0010595 | Colorectum | AD | positive regulation of endothelial cell migration | 40/3918 | 133/18723 | 8.01e-03 | 4.73e-02 | 40 |
GO:0032070 | Colorectum | AD | regulation of deoxyribonuclease activity | 6/3918 | 10/18723 | 8.03e-03 | 4.73e-02 | 6 |
GO:00060911 | Colorectum | SER | generation of precursor metabolites and energy | 168/2897 | 490/18723 | 1.39e-25 | 1.70e-22 | 168 |
GO:00159801 | Colorectum | SER | energy derivation by oxidation of organic compounds | 119/2897 | 318/18723 | 5.28e-22 | 4.62e-19 | 119 |
GO:00432541 | Colorectum | SER | regulation of protein-containing complex assembly | 119/2897 | 428/18723 | 3.34e-11 | 5.86e-09 | 119 |
GO:00098961 | Colorectum | SER | positive regulation of catabolic process | 132/2897 | 492/18723 | 4.16e-11 | 6.72e-09 | 132 |
GO:00458621 | Colorectum | SER | positive regulation of proteolysis | 106/2897 | 372/18723 | 8.40e-11 | 1.20e-08 | 106 |
GO:00313311 | Colorectum | SER | positive regulation of cellular catabolic process | 114/2897 | 427/18723 | 1.22e-09 | 1.27e-07 | 114 |
GO:00510981 | Colorectum | SER | regulation of binding | 97/2897 | 363/18723 | 1.98e-08 | 1.43e-06 | 97 |
GO:00525471 | Colorectum | SER | regulation of peptidase activity | 114/2897 | 461/18723 | 1.18e-07 | 7.17e-06 | 114 |
GO:00525481 | Colorectum | SER | regulation of endopeptidase activity | 103/2897 | 432/18723 | 2.86e-06 | 1.16e-04 | 103 |
GO:00313331 | Colorectum | SER | negative regulation of protein-containing complex assembly | 43/2897 | 141/18723 | 5.03e-06 | 1.86e-04 | 43 |
GO:00109521 | Colorectum | SER | positive regulation of peptidase activity | 55/2897 | 197/18723 | 5.44e-06 | 2.00e-04 | 55 |
GO:00432811 | Colorectum | SER | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 57/2897 | 209/18723 | 8.08e-06 | 2.74e-04 | 57 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HMGB1 | SNV | Missense_Mutation | | c.120N>C | p.Glu40Asp | p.E40D | P09429 | protein_coding | deleterious(0.02) | benign(0.105) | TCGA-D8-A1XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
HMGB1 | SNV | Missense_Mutation | | c.131A>C | p.Lys44Thr | p.K44T | P09429 | protein_coding | deleterious(0.02) | possibly_damaging(0.784) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.624A>T | p.Glu208Asp | p.E208D | P09429 | protein_coding | tolerated_low_confidence(0.26) | benign(0) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.443C>G | p.Ala148Gly | p.A148G | P09429 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
HMGB1 | SNV | Missense_Mutation | novel | c.377C>T | p.Ala126Val | p.A126V | P09429 | protein_coding | deleterious(0.03) | benign(0.221) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.168G>T | p.Glu56Asp | p.E56D | P09429 | protein_coding | deleterious(0.04) | benign(0.105) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
HMGB1 | SNV | Missense_Mutation | | c.253N>G | p.Thr85Ala | p.T85A | P09429 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.23N>G | p.Lys8Arg | p.K8R | P09429 | protein_coding | deleterious(0.02) | benign(0.358) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | novel | c.25N>T | p.Pro9Ser | p.P9S | P09429 | protein_coding | deleterious(0.04) | possibly_damaging(0.573) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HMGB1 | SNV | Missense_Mutation | | c.488G>A | p.Arg163Gln | p.R163Q | P09429 | protein_coding | tolerated(0.16) | benign(0.193) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | PREDNISOLONE | PREDNISOLONE | 18447956 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | AUTOLOGOUS DENDRITIC CELLS | | 16997859 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | ADJUVANT | | 15161015 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | SALINE | SODIUM CHLORIDE | 17334244 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | DISTAMYCIN | | 9161031 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | GP100 | | 16968820 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | CHLORAMPHENICOL | CHLORAMPHENICOL | 9931456 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | EGCG | EPIGALOCATECHIN GALLATE | 17987129 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | MART1 | | 16968820 |
3146 | HMGB1 | DRUGGABLE GENOME, CELL SURFACE, TRANSCRIPTION FACTOR | | AMPICILLIN | AMPICILLIN | 9931456 |